View in EDS PDF Full Text

Restless Legs Syndrome in Patients with Epilepsy Under Levetiracetam Monotherapy.

Saved in:
Bibliographic Details
Title: Restless Legs Syndrome in Patients with Epilepsy Under Levetiracetam Monotherapy.
Alternate Title: Levetirasetam Monoterapisi Altında Epilepsi Hastalarında Huzursuz Bacak Sendromu.
Authors: Kutlu, Gülnihal, Genç, Fatma, Ünal, Yasemin, Öztürk, Dilek Aslan, Erdal, Abidin, Gömceli, Yasemin Biçer
Source: Journal of Turkish Sleep Medicine. Mar2018, Vol. 5 Issue 1, p12-16. 5p.
Subjects: Diagnosis of epilepsy, Anticonvulsants, Drug utilization, Epilepsy, Outpatient services in hospitals, Longitudinal method, Restless legs syndrome, Symptoms
Abstract (English): Objective: Restless Legs syndrome (RLS) is a frequent neurological disease. Levetiracetam (LEV) is an effective and broad-spectrum anticonvulsant drug. The aim of this study is to investigate the frequency of RLS in patients diagnosed with epilepsy who took LEV monotherapy. Materials and Methods: Two neurologists were reviewed the files of 1680 patients, who were followed in epilepsy outpatient clinic. One hundred seven patients under LEV monotherapy for at least six months and 120 healthy controls were included in the study. The criteria for the International Restless Legs Syndrome Study Group were taken into consideration for the assessment of RLS. Results: The mean age of patient group was 38.26±17.39 years, while the mean age of healthy controls was 39.17±16.12 years. There were no statistically significant differences in terms of age and sex between each two groups. The mean duration of LEV usage was 28.34 months. The LEV usage dose was between 500-3000 mg/day. RLS was seen in 7 (5.83%) healthy controls, whereas 4 patients (3.73%) had RLS in patient group before LEV treatment. The symptom of RLS in two patients disappeared after LEV treatment started and this rate decreased to 1.87%. The biochemical parameters were normal in all patient groups, after LEV treatment, peripheral neuropathy was detected in one patient whose symptoms were not relieved. Conclusion: LEV may have therapeutic effect on RLS. It may be preferred especially in comorbid situations where epilepsy and RLS are seen together. Longitudinal and prospective studies are needed to manifest better the therapeutic effects of LEV on RLS. [ABSTRACT FROM AUTHOR]
Abstract (Turkish): Amaç: Huzursuz Bacak sendromu (HBS) sık görülen bir nörolojik hastalıktır. Levetirasetam (LEV) etkili ve geniş spektrumlu bir antiepileptik ilaçtır. Bu çalışmanın amacı epilepsi tanısı ile LEV monoterapisi alan hastalarda HBS sıklığını araştırmaktır. Gereç ve Yöntem: Epilepsi polikliniğinde takip edilen 1680 hastanın dosyası iki nörolog tarafından gözden geçirildi. En az 6 aydır LEV monoterapisi alan 107 hasta ve 120 sağlıklı kontrol çalışmaya alındı. HBS değerlendirmesi için Uluslararası Huzursuz Bacak Sendromu Çalışma Grubu'nun kriterleri göz önüne alındı. Bulgular: Sağlıklı kontrollerin ortalama yaşı 39,17±16,12 yıl iken, hastaların ortalama yaşı 38,26±17,39 yıldı. Her iki grup arasında yaş ve cinsiyet açısından istatistiksel anlamlı bir fark yoktu. Ortalama LEV kullanım süresi 28,34 aydı. LEV kullanım dozu 500-3000 mg/gün arasındaydı. HBS 7 (%5,83) sağlıklı kontrolde görülürken, LEV tedavisi öncesi 4 hasta (%3,73) HBS'ye sahipti. LEV tedavisine başladıktan sonra iki hastanın HBS semptomları kayboldu ve bu oran %1,87'ye geriledi. Tüm hasta grubunun biyokimyasal parametreleri normaldi, LEV tedavisi sonrasında semptomları rahatlamayan bir hastada periferik nöropati saptandı. Sonuç: LEV, HBS üzerinde tedavi edici etkiye sahip olabilir. Özellikle epilepsi ve HBS'nin birlikte görüldüğü komorbid durumlarda tercih edilebilir. LEV'nin HBS üzerindeki tedavi edici etkilerini daha iyi ortaya koyabilmek için longitudinal ve prospektif çalışmalara ihtiyaç vardır. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Turkish Sleep Medicine is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Description
Abstract:Objective: Restless Legs syndrome (RLS) is a frequent neurological disease. Levetiracetam (LEV) is an effective and broad-spectrum anticonvulsant drug. The aim of this study is to investigate the frequency of RLS in patients diagnosed with epilepsy who took LEV monotherapy. Materials and Methods: Two neurologists were reviewed the files of 1680 patients, who were followed in epilepsy outpatient clinic. One hundred seven patients under LEV monotherapy for at least six months and 120 healthy controls were included in the study. The criteria for the International Restless Legs Syndrome Study Group were taken into consideration for the assessment of RLS. Results: The mean age of patient group was 38.26±17.39 years, while the mean age of healthy controls was 39.17±16.12 years. There were no statistically significant differences in terms of age and sex between each two groups. The mean duration of LEV usage was 28.34 months. The LEV usage dose was between 500-3000 mg/day. RLS was seen in 7 (5.83%) healthy controls, whereas 4 patients (3.73%) had RLS in patient group before LEV treatment. The symptom of RLS in two patients disappeared after LEV treatment started and this rate decreased to 1.87%. The biochemical parameters were normal in all patient groups, after LEV treatment, peripheral neuropathy was detected in one patient whose symptoms were not relieved. Conclusion: LEV may have therapeutic effect on RLS. It may be preferred especially in comorbid situations where epilepsy and RLS are seen together. Longitudinal and prospective studies are needed to manifest better the therapeutic effects of LEV on RLS. [ABSTRACT FROM AUTHOR]
ISSN:21481504
DOI:10.4274/jtsm.69188